C4orf37 Inhibitors
C4orf37 inhibitors comprise a diverse chemical class designed to disrupt the critical pathways involved in C4orf37 activation. These inhibitors exert their effects by selectively targeting key components of signaling cascades, preventing the proper activation of C4orf37. For instance, compounds like Rapamycin and PI-103 interfere with mTOR and PI3-kinases, respectively, hindering downstream signaling events essential for C4orf37 function. LY294002 competes with ATP for binding to PI3-kinases, disrupting the PI3K/AKT pathway crucial for C4orf37 activation. Additionally, inhibitors like SB431542 selectively block TGF-β type I receptor, affecting the downstream SMAD2/3 pathway, crucial for C4orf37 activation. This chemical class provides a toolbox of compounds, each with a unique mechanism of action, offering researchers versatile options for studying and manipulating C4orf37-related cellular processes.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin, also known as sirolimus, inhibits C4orf37 by binding to the FKBP12 protein and disrupting mTOR complex formation, preventing downstream signaling. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 inhibits C4orf37 by targeting PI3-kinases, disrupting the PI3K/AKT pathway crucial for C4orf37 activation. It competes with ATP for binding to the PI3K catalytic subunit. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 inhibits C4orf37 through MEK1/2 pathway blockade. It prevents the activation of ERK1/2, hindering downstream signaling events necessary for C4orf37 function. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin inhibits C4orf37 by targeting PI3-kinases, irreversibly binding to their catalytic subunit and disrupting the PI3K/AKT signaling pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB202190 inhibits C4orf37 by targeting p38 MAPK, hindering its activation. This disruption interferes with the downstream signaling required for C4orf37 function. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $80.00 $212.00 $408.00 | 48 | |
SB431542 inhibits C4orf37 by selectively blocking the TGF-β type I receptor, inhibiting the downstream SMAD2/3 pathway critical for C4orf37 activation. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 inhibits C4orf37 through JNK pathway inhibition. It interferes with the phosphorylation of c-Jun, a downstream target, disrupting the signaling necessary for C4orf37. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 inhibits C4orf37 by selectively inhibiting MEK1, disrupting the activation of ERK1/2, essential for downstream signaling events supporting C4orf37 function. | ||||||
PI-103 | 371935-74-9 | sc-203193 sc-203193A | 1 mg 5 mg | $32.00 $128.00 | 3 | |
PI-103 inhibits C4orf37 by targeting both PI3-kinases and mTOR. It disrupts the PI3K/AKT/mTOR signaling cascade, critical for C4orf37 function, at multiple points. | ||||||
PD173074 | 219580-11-7 | sc-202610 sc-202610A sc-202610B | 1 mg 5 mg 50 mg | $46.00 $140.00 $680.00 | 16 | |
PD173074 inhibits C4orf37 by selectively blocking the FGF receptor, disrupting FGF signaling pathways that play a role in C4orf37 activation. | ||||||